Taurian Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 15-06-2024
- Paid Up Capital ₹ 8.44 M
as on 15-06-2024
- Company Age 18 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 27.57%
(FY 2023)
- Profit 8.51%
(FY 2023)
- Ebitda -39.07%
(FY 2023)
- Net Worth 2.08%
(FY 2023)
- Total Assets 2.09%
(FY 2023)
About Taurian Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 8.44 M, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Taurian Pharma Pvt. Ltd. India is Chandrashekhar Bohra as CEO. Sachin Bajla and Chandrashekhar Bohra serve as directors at the Company.
- CIN/LLPIN
U24239MH2006PTC164577
- Company No.
164577
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Sep 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Taurian Pharma Pvt. Ltd. offer?
Taurian Pharma Pvt. Ltd. offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Mineral Supplement, Pharmaceutical Tablets, Caffeine Tablets, Gastrointestinal Drugs, Erectile Dysfunction Medicine, Sildenafil Tablets.
Who are the key members and board of directors at Taurian Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chandrashekhar Bohra  | CEO | 01-Apr-2014 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sachin Bajla | Director | 15-Sep-2006 | Current |
| Chandrashekhar Bohra | Director and Ceo | 01-Aug-2019 | Current |
Financial Performance and Corporate Structure Insights of Taurian Pharma.
Taurian Pharma Pvt. Ltd., for the financial year ended 2023, experienced significant growth in revenue, with a 27.57% increase. The company also saw a slight improvement in profitability, with a 8.51% increase in profit. The company's net worth moved up by a moderate rise of 2.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Taurian Pharma?
In 2023, Taurian Pharma had a promoter holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ambalal Sarabhai Enterprises LimitedActive 46 years 6 monthsChandrashekhar Bohra is a mutual person
- Baidyanath Minerals Private LimitedActive 21 years 11 months
Chandrashekhar Bohra is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Taurian Pharma?
Unlock and access historical data on people associated with Taurian Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Taurian Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Taurian Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
